LMWH therapy after mechanical heart valve replacement
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
Low-molecular-weight heparins (LMWHs) are widely used in the treatment and prevention of deep vein thrombosis and pulmonary embolism. Because of a lack of data, however, use of these agents to reduce the risk of thromboembolism in patients who have had mechanical heart valve replacement (MHVR) is controversial, even though LMWH has a better safety profile than unfractionated heparin (UFH) in these patients. Meurin et al. investigated whether LMWH therapy is a feasible 'bridge' between UFH administration after surgery and anticoagulation with vitamin K antagonists becoming fully effective.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
